AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Enrollment completed for BLP25 liposomal vaccine.
2002 DEC 25 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) announced that the company has completed enrollment of the planned 166 patients in its phase IIb clinical trial with BLP25 Liposomal vaccine.
There are now 168 patients enrolled into the trial. The controlled, randomized study involves patients with advanced non-small cell lung cancer (NSCLC) and enrollment was conducted at 13 sites in Canada and four in the United Kingdom. The trial began in August 2000. Final recruitment in the trial has been extended to allow a few previously identified patients the opportunity to be included in the trial. Enrollment for these identified patients is expected to close later this month.
Since the enrollment of …
- Biomira Completes Enrolment of BLP25 Liposomal Vaccine Phase IIB Study in...
- Press release article from: PR Newswire November 13, 2002 700+ words
...IIIb and IV NSCLC. Patients...to BLP25 Liposomal vaccine, plus best...and Stage IV NSCLC. In this...of BLP25 Liposomal vaccine was increased...and Stage IV NSCLC. Besides the BLP25 Liposomal vaccine Phase IIb...
- Liposomal Vaccine Show Specific Immunotherapy In Stage III Disease.
- Newspaper article from: Biotech Week October 17, 2001 700+ words
...BLP25 (MUCI Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIb-IV NSCLC," the authors concluded...Stage IIIB and Stage IV NSCLC. The Company increased...Stage IIIb and Stage IV NSCLC. The objectives of the...
- Liposomal Vaccine Show Specific Immunotherapy In Stage III Disease.(Brief...
- Newspaper article from: Cancer Weekly October 16, 2001 700+ words
...BLP25 (MUCI Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIb-IV NSCLC," the authors concluded...Stage IIIB and Stage IV NSCLC. The Company increased...Stage IIIb and Stage IV NSCLC. The objectives of the...
- Liposomal Vaccine Shows Specific Immunotherapy In Stage III Disease.(non-small...
- Newspaper article from: Vaccine Weekly October 17, 2001 700+ words
...BLP25 (MUCI Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIb-IV NSCLC," the authors concluded...Stage IIIB and Stage IV NSCLC. The Company increased...Stage IIIb and Stage IV NSCLC. The objectives of the...
- Biomira completes enrolment of BLP25 liposomal vaccine Phase IIB study in...
- News wire article from: Asia Africa Intelligence Wire November 13, 2002 700+ words
...clinical trial with BLP25 Liposomal vaccine. There are now 168...of Stage IIIb and IV NSCLC. Patients were then randomised to BLP25 Liposomal vaccine, plus best supportive...survival benefit of BLP25 Liposomal vaccine in patients with NSCLC...
- Liposomal Vaccine is Immunotherapeutic at Higher Dose.
- Newspaper article from: Vaccine Weekly November 15, 2000 700+ words
...NewsRx.com) -- A liposomal vaccine targeting the MUC1...either stage IIIB or IV NSCLC," stated Martin...MUC1 peptide) liposomal vaccine for active specific...evaluated a MUC1 liposomal vaccine in Stage IIIB and...
- Biomira and Merck KGaA Announce Phase IIb BLP25 Liposomal Vaccine Trial in...
- Press release article from: PR Newswire April 2, 2004 700+ words
...from a randomized, open-label Phase IIb trial of BLP25 liposomal vaccine (L BLP25) in patients with Stage IIIb and IV non- small...the Phase IIb trial for men and women with Stage IIIb and IV NSCLC, in 2002 Biomira also completed enrolment in a second pilot...
- Biomira Provides BLP25 Vaccine Program Update.
- Press release article from: PR Newswire September 24, 2001 700+ words
...Study of the BLP25 (MUCI Peptide) Liposomal Vaccine for Active Specific Immunotherapy in...8 patients with Stage IIIB and Stage IV NSCLC. The Company increased the dose of...in patients with Stage IIIb and Stage IV NSCLC. The objectives of the trial will be...
- FDA grants fast track status for BLP25 Liposome Vaccine.
- Press release article from: PR Newswire September 29, 2004 700+ words
...controlled, randomized Phase IIb study in Stage IIIB and IV NSCLC patients. Results from the Phase IIb study will be presented...Track Drug Product development program the investigation of Liposomal Vaccine in the extension of survival among patients with unresectable...
- Merck KGaA/Biomira's L-BLP25 on fast-track.(Brief Article)
- Newspaper article from: Pharma Marketletter October 4, 2004 700+ words
...granted fast-track status to Biomira/Merck KGaA's BLP25 liposomal vaccine (L-BLP25) for the treatment of non-small cell lung...undergoing a Phase IIb study in patients with stage IIIb and IV NSCLC. Preliminary results from the trial, released earlier this...
Source: HighBeam Research, Enrollment completed for BLP25 liposomal vaccine.
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA
The AccessMyLibrary advertising network includes:
